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Purpose: Anticoagulant therapy has an impact on the health-related quality of life, as it is a
chronic treatment for most clinical indications and also requires some lifestyle changes. Since
there was no validated questionnaire available in the Maltese language, the aim of our study was
to translate and validate the Perception of Anticoagulant Treatment Questionnaire (PACT-Q2).
Patients and methods: The PACT-Q2 explores two dimensions (convenience and antic-
oagulant treatment satisfaction). Forward and backward translations were performed. The
Maltese version of the PACT-Q2 was administered to 174 patients on warfarin treatment
enrolled from different anticoagulation clinics in Malta. Reliability was assessed through
internal consistency (Cronbach’s alpha) and test-retest (intraclass correlation coefﬁcient
[ICC]). Validity was assessed through ﬂoor/ceiling effect, factor analysis (root mean square
error of approximation [RMSEA], standardized root mean squared residual [SRMR], good-
ness-of-ﬁt index [GFI], adjusted goodness-of-ﬁt index [AGFI], comparative ﬁt index [CFI]),
subscales correlation and known-group validity.
Results: Reliability was very good for the convenience subscale (Cronbach’s alpha 0.86,
ICC 0.87), but less good for the satisfaction subscale (Cronbach’s alpha 0.62, ICC 0.40).
Floor effect was 0%; ceiling effect was low (6.3% convenience, 1.2% satisfaction). Fit
parameters were close to acceptable cut-offs (RMSEA =0.09, SRMR =0.10, GFI =0.82,
AGFI =0.78, CFI =0.79). There was no correlation between the two subscales (r=0.01,
p=0.83). Patients with history of bleeding showed lower convenience (r=−0.16, p=0.08)
and lower satisfaction (r=−0.21, p=0.01).
Conclusions: Our results support the ﬁnding that the Maltese translation of the PACT-Q2 is
a valid and reliable instrument.
Keywords: atrial ﬁbrillation, psychometrics, quality of life, surveys and questionnaires,
venous thromboembolism, warfarin
Introduction
Anticoagulant therapy is the mainstay treatment for the primary and secondary
prevention of thromboembolic complications in patients with atrial ﬁbrillation
(AF), venous thromboembolism (VTE) and mechanical heart valve replacement.1
However, since it is a chronic treatment for most clinical indications, it can affect
the health-related quality of life.2,3 For instance, vitamin K antagonists (VKA), such
as warfarin, have several food and drug interactions and require dose adjustment,
therefore mandating periodic blood testing of the international normalized ratio
(INR).1
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Since patients’ negative beliefs related to medications
can result in non-adherence to chronic treatment and there-
fore reduced effectiveness,4,5 speciﬁc questionnaires have
been developed to assess the satisfaction associated with
the anticoagulant treatment. These include the Perception
of Anticoagulant Treatment Questionnaire (PACT-Q),6 the
Duke Anticoagulation Satisfaction Scale (DASS),7 the
Anti-Clot Treatment Scale (ACTS),8 the Deep Venous
Thrombosis Quality of Life questionnaire (DVTQOL)9
and the Pulmonary Embolism Quality of Life
Questionnaire (PEmb-QoL).10 However, there was no vali-
dated questionnaire available in the Maltese language.
We chose to translate the PACT-Q and the DASS
because they have already been translated into several
languages and applied to patients with a broad range of
clinical indications to the anticoagulant treatment.7,11–15
The aim of this study was to assess the psychometric
properties (reliability and validity) of the Maltese version
of the PACT-Q. The psychometric properties of the
Maltese version of the DASS have been reported in a
separate paper.
Materials and methods
The perception of anticoagulant
treatment questionnaire (PACT-Q)
The PACT-Q is divided into two parts: the PACT-Q1
measures the expectations associated with the anticoagu-
lant treatment and is administered prior to treatment
initiation, while the PACT-Q2 measures the convenience
and the satisfaction and is administered during anticoa-
gulant treatment.6,11 In the PACT-Q2, the “Convenience”
dimension comprises 13 items (from the combination of
the original sections B “Convenience” and C “Burden of
Disease and Treatment”), while the “Anticoagulant
Treatment Satisfaction” dimension comprises 7 items
(section D).11 All items can be answered according to a
5-point Likert scale (not at all, a little, moderate, a lot,
extremely). During the analysis, the items of
“Convenience” are reversed, summed and rescaled on a
0–100 scale; the items of “Anticoagulant Treatment
Satisfaction” are summed and rescaled on a 0–100
scale. Therefore, higher total scores correspond to higher
convenience/satisfaction.11
Permission to translate and use the PACT-Qwas obtained
from Sanoﬁ Aventis/Mapi Research Trust. The linguistic
validation process followed published guidelines,16,17 with
two forward translations from English to Maltese and a
backward translation from Maltese to English, performed
by different people (a professional translator, a health psy-
chologist, and a speech and language pathologist), all bilin-
gual in English and Maltese. A pilot testing was initially
performed by completing and discussing the questionnaire
with 5 patients on long-term oral anticoagulant treatment (not
included in the analysis).
Study population
We administered the Maltese version of the PACT-Q2 to
174 patients receiving warfarin treatment. They were
enrolled from the Anticoagulation Clinics at Mater Dei
Hospital (Msida) and at 5 Health Centers (Cospicua,
Floriana, Mosta, Qormi, Rabat) in Malta. Blood samples
for INR testing at Mater Dei Hospital are collected using
traditional venepuncture and INR is performed using
laboratory coagulometers, whilst at the Health Centres
INR is tested using point-of-care devices. Patients with
cognitive impairment, dementia or major psychiatric dis-
orders (such as schizophrenia) were excluded.
Two authors (NR, CBX) distributed the questionnaires
between July 2017 and February 2018. Since we consid-
ered patients already receiving the anticoagulant treatment,
only the PACT-Q2 was administered. Patients were also
asked to complete a form on sociodemographic data. To
ensure anonymity, questionnaires were identiﬁed using a
code. In case of missing answers, the researchers asso-
ciated the code with the provided demographic details and
patients were contacted by phone.
During the same period, 157 patients on warfarin
enrolled from the same Anticoagulation Clinics completed
the original English version of the PACT-Q2.
A random sample of 40 patients underwent the follow-
ing test-retest after 1–2 weeks (10 patients for each type):
Maltese–Maltese; English–English; Maltese–English;
English–Maltese.
This study was approved by the University of Malta
Research and Ethics Committee (Ref No 07/2016) and all
patients signed a written informed consent form before
inclusion.
Statistical analysis
Continuous variables were reported as mean±standard
deviation (SD), while categorical variables were reported
as counts and percentages. Continuous variables were
compared using the Student’s independent samples t-test,
while categorical variables were compared using the Chi-
square or the Fisher’s exact tests, as appropriate.
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We evaluated the reliability of the Maltese version of the
PACT-Q2 through internal consistency and test–retest.18
The Cronbach’s alpha coefﬁcient was used to assess the
internal consistency, with a value ≥0.70 indicating high
internal consistency.19
A test–retest was performed to assess reproducibility,
and we calculated the intraclass correlation coefﬁcients
(ICC) for the intra-language correlation (Maltese-Maltese
and English–English test–retest). Values between 0.60 and
0.74 are considered acceptable.20 For the cross-language
correlation (Maltese–English and English–Maltese test-ret-
est pooled together), we calculated the raw and the
adjusted cross-language correlation (dividing the raw
cross-language correlation by the square-root of the pro-
duct of the intra-language correlations, to adjust for score
unreliability).21,22
We evaluated the validity of the Maltese translation of
the PACT-Q2 through ﬂoor and ceiling effect, factor ana-
lysis, construct validity and known-group validity. Floor
and ceiling effect occur when more than 15% of the
respondents achieve the lowest or the highest possible
score, respectively.23
In the factor analysis, convergent and discriminant
validity were evaluated. The convergent validity criterion
was considered met when the correlation between each
item and its dimension was ≥0.40, while the discriminant
validity criterion was considered met when each item
showed higher correlation with its dimension than the
other.24 We conducted an exploratory factor analysis with
varimax rotation to examine the structure of the PACT-Q2.
A subsequent conﬁrmatory factor analysis provided the
following ﬁt parameters: root mean square error of approx-
imation (RMSEA ≤0.05 good ﬁt, ≤0.08 acceptable ﬁt);
standardized root mean squared residual (SRMR ≤0.05
good ﬁt, ≤0.10 acceptable ﬁt); goodness-of-ﬁt index
(GFI), adjusted goodness-of-ﬁt index (AGFI) and com-
parative ﬁt index (CFI), with values ≥0.90 considered
acceptable.25
To examine construct validity, the Pearson’s correlation
between different subscales was assessed.26 Known-group
validity was assessed through Pearson’s correlation
between the score of each PACT-Q2 subscale and the fol-
lowing variables: increasing age; male sex; living alone;
primary school education only; paid employment; atrial
ﬁbrillation; anticoagulant treatment duration (>5 years);
INR in the therapeutic range at enrolment; time-within-
therapeutic-range (TTR, calculated according to the
Rosendaal method)27 ≥70% in the previous year;
hospitalization in the previous year; history of any bleeding
during anticoagulant treatment (self-reported).
A sample size of at least 150 patients was planned,
since recommendations suggest at least 50 patients23 and
previous validation studies enrolled around 100
patients.28,29
The statistical software STATA SE v.12 (StataCorp LP,
College Station, TX, USA) and SAS v. 9.4 (SAS Institute
Inc, Cary, NC, USA) were used for statistical analysis, with
two-tailed p-values<0.05 considered statistically signiﬁcant.
Results
Study population
Baseline characteristics of the study population are sum-
marized in Table 1. The comparison between patients who
completed the Maltese and the English version of the
questionnaires has been already reported.
There was no difference in the mean convenience score
between the two cohorts (mean±SD 82.2±16.1 for theMaltese
version vs 84.0±13.7 for the English version, p=0.28), while
patients who completed the Maltese version showed a trend
toward lower satisfaction score (65.2±11.5 vs 67.6±14.6,
Table 1 Characteristics of patients who completed the Maltese
version of the PACT-Q2
N of patients 174
Age (years), mean (SD) 70 (10.1)
Males, n/N (%) 82/174
(47.1%)
Living alone, n/N (%) 31/174
(17.8%)
Primary school education only, n/N (%) 108/174
(62.1%)
Paid employment (full- or part-time), n/N (%) 18/174
(10.3%)
Anticoagulant indications: atrial ﬁbrillation, n/N (%) 122/174
(70.1%)
Anticoagulant treatment duration: >5 years, n/N (%) 76/174
(43.7%)
INR in range at enrolment, n/N (%) 99/174
(56.9%)
Good anticoagulation control (TTR ≥70%) in the
previous 12 months, n/N (%)
96/170
(56.5%)
Hospitalisation in the previous 12 months, n/N (%) 86/170
(50.6%)
History of bleeding (self-reported), n/N (%) 63/174
(36.2%)
Abbreviations: INR, international normalized ratio; SD, standard deviation; TTR,
time within therapeutic range.
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respectively, p=0.09), corresponding to lower anticoagulant
treatment satisfaction.
Internal consistency
The internal consistency of the Maltese translation of the
PACT-Q2 was good for the convenience subscale with
Cronbach’s alpha coefﬁcient of 0.86. Cronbach’s alpha was
0.62 for the satisfaction subscale, which is slightly below the
standard acceptable cut-off of 0.70. However, the satisfaction
subscale has only 7 items and one item (D2) showed poor
correlation with the overall satisfaction subscale, showing
both a low item-total correlation of ~0.3 and an increase of
Cronbach’s alpha when deleted. However, D2 corresponds to
the question “Do you feel that your anticoagulant treatment
has decreased your symptoms?”, which might have a nega-
tive answer also in satisﬁed patients, if anticoagulation is
used for stroke prevention in atrial ﬁbrillation or mechanical
heart valves, and therefore does not have any impact on
patients’ symptoms.
The English version of the PACT-Q2 also showed good
internal consistency in our cohort with the following
Cronbach’s alpha coefﬁcients: 0.86 for the convenience
subscale and 0.75 for the satisfaction subscale (Table 2).
Reproducibility
In the Maltese–Maltese test–retest, the ICC for the intra-
language correlation was very good for the convenience
subscale (0.87), but low (0.40) for the satisfaction sub-
scale. In the English–English test–retest, ICC was 0.87 for
the convenience subscale and 0.60 for the satisfaction
subscale (Table S1).
For the cross-language correlation, the corresponding
ICC was 0.51 and 0.52 and the adjusted ICC was 0.59 and
1.06 for the convenience and satisfaction subscales, respec-
tively. When analyzed separately, ICC for the English–
Maltese test–retest was 0.76 and 0.68 for the convenience
and satisfaction subscales, while ICC for the Maltese–
English test–retest was 0.43 and 0.41, respectively.
Floor and ceiling effect
When we analyzed the response distribution for each item
of the PACT-Q2, reversing the items of the convenience
subscale, a signiﬁcant ceiling effect was observed for most
of the questions. A signiﬁcant ﬂoor effect was found only
for question D2. The Maltese and the English version of
the PACT-Q2 showed similar results in our study
(Table S2).
We subsequently analyzed the results of each PACT-
Q2 subscale: for the Maltese version, ceiling effect was
6.3% for convenience and 1.2% for satisfaction; for the
English version, ceiling effect was 9.6% for convenience
and 1.3% for satisfaction. Floor effect was 0% for all
subscales in both languages.
Factor analysis
Results of the conﬁrmatory factor analysis were accepta-
ble. For the Maltese version of the PACT-Q2, SRMR=0.10
was within the acceptable limits; RMSEA=0.09 was
slightly above the reference, while GFI=0.82, AGFI=0.78
and CFI=0.79 were slightly below the reference values
(Table 3).
The rotated factor pattern is reported in Table S3. The
convergent validity criterion was met by all items of the
Maltese PACT-Q2, except B10, B11, C2 (for the conve-
nience subscale) and D2, D3 (for the satisfaction sub-
scale). All items met the discriminant validity criterion.
Correlation scale-subscales
There was no correlation between the convenience and the
satisfaction subscales in the Maltese version of the PACT-
Q2 (r=0.01, p=0.83), while a weak positive correlation was
found in the English version (r=0.33, p<0.001).
Known-group validity
The Maltese version of the PACT-Q2 showed a negative
correlation with previous bleeding. The correlation was
statistically signiﬁcant for the satisfaction subscale and
borderline for the convenience subscale (Table 4).
In the English version of the PACT-Q2, the conveni-
ence subscale showed a signiﬁcant positive correlation
with increasing age and male sex, and a signiﬁcant nega-
tive correlation with full- or part-time paid employment,
hospitalization and history of bleeding. The subscale satis-
faction gave similar results, which were statistically sig-
niﬁcant only for male sex.
These ﬁndings suggest that advanced age and male sex
are associated with greater satisfaction/convenience, while
paid employment, hospitalization and previous bleeding
are associated with lower satisfaction/convenience.
Discussion
To the best of our knowledge, this is the ﬁrst time that the
PACT-Q2 has been translated and validated in the Maltese
language. The results of our study suggest that the Maltese
version of the PACT-Q2 is a valid and reliable instrument.
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The psychometric properties were very good for the conve-
nience subscale, whereas they were slightly lower for the
satisfaction subscale.
The PACT-Q is a speciﬁc questionnaire that evaluates
the quality of life of anticoagulated patients through simple
questions. It was rigorously developed, translated in several
languages and used in a number of studies enrolling patients
with different clinical indications.14,30–32 While the PACT-
Q1 assesses the expectations of the anticoagulant treatment,
the PACT-Q2 evaluates the satisfaction and is used for
patients already receiving the anticoagulant treatment.
Patient-reported outcomes should always be considered,
because of the relationship between low satisfaction, poor
adherence and treatment failure.33–35 In our study, we trans-
lated the PACT-Q2 in Maltese and administered it to 174
patients on warfarin for different clinical indications,
including atrial ﬁbrillation, heart valve replacement and
venous thromboembolism. A peculiarity of our study is
the fact that during the same time-frame, the original
English version of the PACT-Q2 was administered to 157
patients at the same centers, therefore allowing a compar-
ison of the psychometric properties. This study design was
possible because Malta is a bilingual country where both
Maltese and English are ofﬁcial languages.36
We found that the reliability of the Maltese translation of
the PACT-Q2 was very good for the convenience subscale
(Cronbach’s alpha 0.86, ICC 0.87), while it was less so for
the satisfaction subscale (Cronbach’s alpha 0.62, ICC 0.40).
However, the satisfaction subscale showed lower reliability
also in the English version of the PACT-Q2 (Cronbach’s
alpha 0.75, ICC 0.60 in our study; Cronbach alpha 0.76 in
the study by Prins et al).11 This ﬁnding can be partly explained
by the lower number of items (13 questions in the convenience
subscale vs 7 questions in the satisfaction subscale) and partly
by a response bias. Response bias is common in patient-
reported outcomes and occurs when participants’ responses
are inﬂuenced by their belief of which answers are socially
acceptable or which answers are expected by the researchers.37
The satisfaction subscale might have been particularly suscep-
tible to response bias, due to the fact that several questions (D4-
D7) ask directly the level of satisfaction with different aspects
of the anticoagulant treatment (the level of independence, the
appointments, the anticoagulant drug and the overall satisfac-
tion). Participants might have felt more obliged to show that
they were satisﬁed with the service, appointments,
Table 3 Results of the conﬁrmatory factor analysis
Fit para-
meters
Reference
values25
Maltese
version of
the PACT-
Q2
English ver-
sion of the
PACT-Q2
RMSEA ≤0.08 0.09 0.07
SRMR ≤0.10 0.10 0.08
GFI ≥0.90 0.82 0.80
AGFI ≥0.90 0.78 0.84
CFI ≥0.90 0.79 0.88
Abbreviations: Legend, AGFI, adjusted goodness-of-ﬁt index; CFI, comparative ﬁt
index; GFI, goodness-of-ﬁt index; RMSEA, root mean square error of approxima-
tion; SRMR, standardized root mean squared residual.
Table 4 Correlation between the PACT-Q2 and sociodemographic or clinical characteristics
Variable Correlation coefﬁcient for
the Maltese version
(p-value)
Correlation coefﬁcient for
the English version
(p-value)
Convenience Satisfaction Convenience Satisfaction
Increasing age 0.05 (0.53) 0.02 (0.81) 0.34 (<0.0001) 0.14 (0.08)
Male sex 0.09 (0.26) 0.03 (0.68) 0.27 (0.001) 0.19 (0.02)
Living alone 0.05 (0.54) −0.11 (0.14) −0.07 (0.37) 0.05 (0.55)
Primary school education only −0.01 (0.95) −0.07 (0.36) −0.02 (0.84) −0.11 (0.16)
Paid (full- or part-time) employment −0.09 (0.24) 0.04 (0.56) −0.22 (0.006) −0.15 (0.07)
Atrial ﬁbrillation −0.01 (0.94) 0.04 (0.58) 0.09 (0.27) 0.01 (0.91)
Anticoagulant treatment duration >5 years 0.03 (0.73) 0.07 (0.36) 0.05 (0.57) 0.01 (0.92)
INR in range at enrolment 0.05 (0.49) 0.05 (0.43) 0.07 (0.36) −0.15 (0.07)
Good anticoagulation control (TTR ≥70%) in the previous 12 months 0.06 (0.43) 0.12 (0.12) 0.04 (0.64) −0.03 (0.71)
Hospitalisation in the previous 12 months −0.10 (0.21) −0.03 (0.70) −0.18 (0.03) 0.05 (0.58)
History of bleeding (self-reported) −0.16 (0.08) −0.21 (0.01) −0.17 (0.03) −0.12 (0.11)
Note: A negative correlation means lower satisfaction.
Abbreviations: INR, international normalized ratio; TTR, time within therapeutic range.
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anticoagulant drug rather than risk reprisal on their treatment,
even though the informed consent speciﬁed anonymity of data.
Furthermore, although the retest was performed within two
weeks, changes in the level of satisfactionmight have occurred
due to intercurrent clinical complications or differences of
experience of service provision during following appointments
for INR testing.
Validity of the Maltese translation of the PACT-Q2 was
good. We observed a signiﬁcant ceiling effect for most of
the PACT-Q2 items when analyzed individually. However,
when we considered the two subscales, ﬂoor effect was 0%
and ceiling effect did not exceed 10% (being 6.3% for
convenience and 1.2% for satisfaction). These results were
even better than the original study of the PACT-Q2 which
reported a ceiling effect of 22.1% for convenience and 3.3%
for satisfaction.11 Results of the factor analysis were good,
with ﬁt parameters close to the acceptable cut-offs.
Furthermore, all items met the discriminant validity criter-
ion, while the convergent validity was met by all items
except B10, B11, C2 (convenience subscale) and D2, D3
(anticoagulant treatment satisfaction subscale). Although
previous studies did not report the ﬁt parameters
(RMSEA, SRMR, GFI, AGFI and CFI), items B10-B11
and D2-D3 did not meet the convergent validity criterion
also in the original study by Prins et al.11 Correlation
between the two PACT-Q2 subscales was weak, as pre-
viously reported,11 conﬁrming that they cover different
dimensions. The results of the known-group validity analy-
sis showed that patients with history of bleeding had lower
satisfaction. Although previous validation studies of the
PACT-Q did not evaluate this group,11,12 lower scores on
the convenience dimension of the PACT-Q2 were reported
after bleeding events in a prospective study enrolling 807
atrial ﬁbrillation patients on warfarin.31 Furthermore, lower
satisfaction in anticoagulated patients with history of bleed-
ing was already reported in validation studies of other
speciﬁc questionnaires.7,38
Our study population shows some differences when
compared to previous PACT-Q validation studies. Mean
age was older (70 years), compared to 65 years in the
study by Prins et al11 and 58 years in the study by
Mohamed et al.12 We enrolled patients on oral anticoagu-
lant treatment with VKA, while Prins et al11 considered
also patients on treatment with idraparinux, which is a
parenteral drug injected subcutaneously once weekly.
Finally, we had a higher proportion of patients with pri-
mary school level of education (62%), compared to the
study by Mohamed et al12 where only 28% had only
primary school education or no education at all.
Our study has also some limitations which need to be
acknowledged. First, we enrolled patients who were
already on anticoagulant treatment; therefore, we could
validate only the PACT-Q2. Second, although the PACT-
Q has been developed for patients receiving different types
of anticoagulants (oral or parenteral),6 we enrolled only
patients on warfarin which was the main oral anticoagulant
treatment in Malta at the time of patients enrolment.
Nonetheless, the strengths of our study include the com-
pleteness of data, without any missing answers, and the
rigorous process of translation and analysis.
Conclusion
Our results support the ﬁnding that the Maltese translation
of the PACT-Q2 is a valid and reliable instrument, which
can be used by health-care professionals when assessing
Maltese-speaking anticoagulated patients.
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Supplementary material
Table S1 Details of the intra-language correlation: score differences on re-administration of the PACT-Q2 (time 2 minus time 1) and
intraclass correlation coefﬁcients
Mean score difference (SD) Min score difference Max score difference ICC
Maltese–Maltese
PACT-Q2 convenience −0.1 (3.2) −6 6 0.87
PACT-Q2 satisfaction 0.1 (4.1) −7 8 0.40
English–English
PACT-Q2 convenience 0.9 (3.0) −3 7 0.87
PACT-Q2 satisfaction 2.3 (3.6) −1 +10 0.60
Note: For both subscales, the original scores were considered (not rescaled). Items in the convenience subscale were reversed.
Abbreviations: ICC, intraclass correlation coefﬁcient; SD, standard deviation.
Table S2 Response distribution for each PACT-Q2 item and summary statistics
PACT-Q2 item Maltese version English version
Response category (%) Mean (SD) Response category (%) Mean (SD)
1 2 3 4 5 1 2 3 4 5
B1* 1.2 5.2 4.0 12.1 77.6 4.6 (0.9) 0.6 1.3 5.7 14.0 78.3 4.7 (0.7)
B2* 2.9 6.3 8.6 20.1 62.1 4.3 (1.1) 0.0 5.1 6.4 16.6 72.0 4.6 (0.8)
B3* 4.0 5.8 6.3 24.1 59.8 4.3 (1.1) 0.0 2.6 9.6 26.1 61.8 4.5 (0.8)
B4* 5.2 12.6 8.6 24.1 49.4 4.0 (1.2) 2.6 11.5 19.1 26.8 40.1 3.9 (1.1)
B5* 2.9 10.3 15.5 21.8 49.4 4.0 (1.2) 1.3 8.3 19.8 29.3 41.4 4.0 (1.0)
B6* 2.9 8.1 4.0 10.3 74.7 4.5 (1.1) 0.6 2.6 7.6 21.0 68.2 4.5 (0.8)
B7* 1.7 4.6 9.8 18.4 65.5 4.4 (1.0) 1.9 3.8 8.3 26.1 59.9 4.4 (0.9)
B8* 1.2 4.0 7.5 14.4 73.0 4.5 (0.9) 1.3 6.4 8.9 27.4 56.1 4.3 (1.0)
B9* 0.6 4.0 4.6 6.9 83.9 4.7 (0.8) 0.6 1.9 2.6 17.2 77.7 4.7 (0.7)
B10* 5.2 8.1 5.2 17.8 63.8 4.3 (1.2) 1.3 3.2 3.8 13.4 78.3 4.6 (0.8)
B11* 11.5 17.8 29.5 24.1 27.0 3.4 (1.4) 8.3 17.8 19.1 26.1 28.7 3.5 (1.3)
C1* 2.3 4.0 6.9 10.9 75.9 4.5 (1.0) 0.0 4.5 10.8 14.0 70.7 4.5 (0.9)
C2* 2.3 8.6 10.9 25.3 52.9 4.2 (1.1) 0.6 2.6 7.0 28.0 61.8 4.5 (0.8)
D1 2.3 2.9 27.0 57.5 10.3 3.7 (0.8) 6.4 8.3 14.6 39.5 31.2 3.8 (1.2)
D2 51.2 14.9 6.9 16.7 10.3 2.2 (1.5) 42.7 16.6 19.1 14.0 7.6 2.3 (1.3)
D3 4.0 5.8 50.6 28.7 10.9 3.4 (0.9) 0.6 3.2 54.1 21.7 20.4 3.6 (0.9)
D4 0.6 2.9 12.6 72.4 11.5 3.9 (0.6) 0.6 1.9 11.5 64.3 21.7 4.0 (0.7)
D5 0.0 5.8 9.8 71.3 13.2 3.9 (0.7) 1.3 5.1 12.7 53.5 27.4 4.0 (0.9)
D6 0.0 0.6 6.3 81.6 11.5 4.0 (0.4) 1.3 0.6 7.0 68.8 22.3 4.1 (0.7)
D7 0.0 0.0 5.8 78.7 15.5 4.1 (0.5) 1.3 1.3 7.6 64.3 25.5 4.1 (0.7)
Notes: Numbers in bold in the response category section indicate signiﬁcant ﬂoor or ceiling effect. * Items of the convenience subscale (B1 to C2) are reversed.
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Table S3 Results of the 2-factor analysis
Maltese version English version
Item Convenience Satisfaction Convenience Satisfaction
B1* 0.69 0.09 0.63 0.06
B2* 0.78 0.26 0.69 0.34
B3* 0.64 0.07 0.69 0.06
B4* 0.70 −0.03 0.57 −0.03
B5* 0.53 0.04 0.53 0.10
B6* 0.60 −0.08 0.60 0.16
B7* 0.62 0.32 0.56 0.18
B8* 0.63 0.13 0.63 0.25
B9* 0.70 0.07 0.72 0.05
B10* 0.34 0.09 0.22 0.15
B11* 0.36 0.07 0.38 0.11
C1* 0.46 −0.08 0.55 0.08
C2* 0.38 0.03 0.58 0.11
D1 −0.06 0.42 0.08 0.37
D2 −0.36 0.29 −0.07 0.25
D3 0.10 0.27 0.15 0.39
D4 0.20 0.49 0.38 0.55
D5 0.16 0.58 0.14 0.75
D6 0.03 0.75 0.17 0.89
D7 −0.10 0.83 0.18 0.91
Notes: Numbers in bold indicate the highest loading of each factor, which is therefore likely to explore that dimension. * Items of the convenience subscale (B1 to C2) are
reversed.
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